<DOC>
	<DOCNO>NCT00014352</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . Anticoagulant drug warfarin may reduce risk blood clot . PURPOSE : Phase II trial study effectiveness combination chemotherapy plus warfarin treating patient prostate cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Warfarin Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety , efficacy , durability docetaxel estramustine follow doxorubicin ketoconazole patient high-risk , androgen-independent prostate cancer . II . Determine whether anticoagulation warfarin reduce frequency thromboembolic complication associate estramustine patient . OUTLINE : Regimen A : Patients receive oral estramustine 3 time daily day 1-5 docetaxel IV 1 hour day 3 weekly . Patients also receive oral warfarin daily . Treatment repeat every 4 week total 2 course absence disease progression unacceptable toxicity . Regimen B : After completion regimen A , patient receive doxorubicin IV 30 minute weekly oral ketoconazole twice daily . Treatment repeat every 4 week total 2 course absence disease progression unacceptable toxicity . Patients follow monthly disease progression . PROJECTED ACCRUAL : A total 50 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Estramustine</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm prostate cancer High risk define 2 following : Karnofsky performance status 7080 % Lactate dehydrogenase great 200 U/mL Hemoglobin le 13 g/dL Prostatespecific antigen ( PSA ) least 4 ng/mL Progressive disease base 1 follow : Rise PSA level least 25 % baseline At least 3 determination take weekly interval OR At least 2 determination take monthly interval New progressive soft tissue mass MRI CT scan Radionucleotide bone scan new metastatic lesion ( ) Serum testosterone great 30 ng/mL If prior surgical orchiectomy , castrate level serum testosterone must maintain continuation gonadotropin release hormone analog If receive antiandrogen , must show progression disease stop antiandrogen therapy PATIENT CHARACTERISTICS : Age : 18 Performance status : See Disease Characteristics Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : See Disease Characteristics WBC least 3,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin normal SGOT/SGPT great 1.5 time upper limit normal ( ULN ) Renal : Creatinine great 1.5 time ULN Cardiovascular : No significant cardiovascular disease No New York Heart Association class III IV heart disease No active angina pectoris No myocardial infarction within last 6 month Ejection fraction least 45 % echocardiogram MUGA No prior hemorrhagic thrombotic cerebral vascular accident No deep venous thrombosis Pulmonary : No pulmonary embolism within past 6 month Other : No history bleed disorder gastrointestinal bleeding would preclude anticoagulation warfarin No concurrent malignancy except nonmelanoma skin cancer curatively treat malignancy consider less 30 % risk relapse No severe infection No severe malnutrition No serious medical illness would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No 1 prior chemotherapy regimen Endocrine therapy : See Disease Characteristics Radiotherapy : No 1 prior course palliative radiotherapy No 1 prior radioisotope therapy strontium chloride Sr 89 samarium Sm 153 lexidronam pentasodium Surgery : See Disease Characteristics At least 4 week since prior major surgery</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>thromboembolism</keyword>
</DOC>